The in vitro aictivity of A-56268 was determined and compared with that of erythromycin and clindamycin against a Unlited spectrum of 401 gram-positive and gram-negative organisms. A-56268 
The macrolide antibiotics consist of a macrocyclic lactone ring attached to two sugar moieties (7) . The only such agents currently available in the United States are erythromycin and troleandomycin, an acetylated ester of oleandomycin. Spiramycin, a third macrolide, available only for investigations in the United States, is used clinically in other countries. Erythromycin is the most widely used macrolide agent and is often prescribed as an alternative to the penicillins in the treatment of infections due to gram-positive organisms in penicillin-allergic individuals (7) . Its spectrum of activity also includes Mycoplasma pneurnoniae, Chlamydia trachomatis, and a number of gram-negative organisms, such as Neisseria spp. Haemophilus influenzae, Legionella spp., and Campylobacter spp. (1) (2) (3) (4) 6) .
A-56268 (TE-031) is a new macrolide agent structurally similar to erythromycin, differing only by the substitution of a methoxy group at the sixth carbon of the erythronilide ring of erythromycin base. Limited information is available concerning the pharmacokinetic properties or in vitro activity of this agent. We studied the in vitro activity of A- overnight incubation at the appropriate temperature for the organisms. The MICs and MBCs of A-56268 and erythromycin for 16 enterococci, 28 staphylococci, 10 S. pneumoniae isolates, 8 group A streptococci, 7 group B streptococci, and 6 L. monocytogenes isolates were determined by using a microtiter broth dilution technique. The organisms for which MBCs were determined had agar dilution MICs of less than 32 ,ug/ml for the antibiotics tested. National Committee for Clinical Laboratory Standards bulk broth dilution schemes were used to prepare the antimicrobial solutions, and 100-,ul samples were added to each well in 96-well microtiter trays. Antimicrobial solutions were prepared in Mueller-Hinton broth for staphylococci and enterococci and in MuellerHinton broth containing 2 to 3% lysed horse blood for the remaining organisms. The standardized bacterial suspensions were diluted to achieve a concentration of 106 CFU/ml, and 100 Ru of the inocula was added to each well. Judged by quantitative colony counts, the final concentration of bacteria in each well was determined to be at least 5 x 105 CFU/ml. The MIC was determined visually after incubation for 24 h at 37°C. The MBCs were determined by subculturing 0.01 ml from each well without visible growth onto appropriate antibiotic-free media and incubating the subculture overnight. The MBC was defined as the lowest concentration of antibiotic resulting in a 99.9% decline in colony count of the subculture inoculum. S. faecalis ATCC 29212 and S. aureus ATCC 25923 were used as controls.
The antibacterial activities of A-56268, erythromycin, and selected antibiotics for 401 gram-positive and gram-negative organisms are presented in Table 1 . A-56268 demonstrated activity comparable to that of erythromycin against erythromycin-sensitive S. aureus and erythromycin-sensitive Staphylococcus epidermidis but was not active against enterococci, erythromycin-resistant S. aureus or erythromycin-resistant S. epidermidis. The MIC for 90% of the strains tested with A-56268 was equal to or within 1 dilution of that of erythromycin for Haemophilus spp., N. gonorrhoeae, L. monocytogenes, Corynebacterium group JK, C. coli, Campylobacter fetus subsp. fetus, Salmonella enteritidis, Shigella spp., Vibrio spp., Y. enterocolitica, and streptococci of groups B, C, D, and G. A-56268 was slightly more active than erythromycin against S. pneumoniae and group A streptococci. It was leSs active than erythromycin against C. jejuni. As previously described by Fliegelman et al., C. coli as well as some C. jejuni isolates were resistant to erythromycin, and this resistance extended also to A-56268 (2). Overall, A-56268 was most active against erythromycinsensitive S. aureus, N. gonorrhoeae, L. monocytogenes, S. pneumoniae, and nondnterococcal streptococci. A-56268 was bactericidal for only 27 of the 75 organisms for which MBCs of A-56268 and erythromycin were determined. Erythromycin was bactericidal for 32 of the 75 organisms. A-56268 was most consistently bactericidal for S. pneumoniae.
While A-56268 was quite active in vitro against erythromycin-sensitive staphylococci, N. gonorrhoeae, L. monocytogenes, S. pneurnoniae, and nonenterococcal streptococci and was moderately active against Haemophilus spp. and C. jejuni, it did not offer a decisive improvement over the activity of erythromycin. The bactericidal activity of A-56268 was comparable to that of erythromycin. Those organisms resistant to erythromycin appeared to be equally resistant to A-56268.
The lack of a definitive antimicrobial advantage in the in vitro activity of A-56258 compared with erythromycin suggests that its utility as a therapeutic agent will be determnined either by an improvement in the in vitro activity against other susceptible organisms, such as Mycoplasma spp., Chlamydia spp., or Legionella spp., or improved pharmacokinetic properties compared with those of erythromycin. Further in vitro and pharmacokinetic studies are warranted to determine the appropriate place for this agent in the antimicrobial pharmacopoeia.
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